Corcept Therapeutics Q4 Revenue Climb Bolstered by Korlym, Pipeline Costs Rise
Corcept Therapeutics posted year-over-year revenue growth in Q4 2025 driven by expanded Korlym prescriptions, marking its third consecutive quarter of top-line improvement. R&D expenses rose on accelerated Phase 3 relacorilant trials, narrowing operating margins and prompting management to maintain full-year expense guidance.
1. Q4 Financial Results
Corcept delivered sequential and year-over-year revenue growth in Q4 2025, primarily fuelled by a rise in Korlym prescriptions. Gross margins contracted slightly as operating expenses outpaced sales growth, resulting in a modest reduction in operating income compared with the prior quarter.
2. Pipeline Progress
The company accelerated its Phase 3 relacorilant program for Cushing’s syndrome and solid tumors, driving a 25% jump in R&D spending. Management highlighted upcoming trial readouts expected in mid-2026, underscoring the strategic focus on broadening its pipeline beyond Korlym.
3. Financial Guidance and Outlook
Despite margin pressure, leadership reaffirmed full-year expense guidance and maintained a cash runway through 2027. The outlook balances ongoing investment in relacorilant development with disciplined cost management to sustain both growth and liquidity.